Caxton Associates (New York)’s PDL BioPharma, Inc. PDLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-87,446
| Closed | -$275K | – | 359 |
|
|
2020
Q3 | $275K | Buy |
+87,446
| New | +$275K | 0.03% | 201 |
|
|
2020
Q1 | – | Sell |
-262,508
| Closed | -$852K | – | 657 |
|
|
2019
Q4 | $852K | Buy |
262,508
+186,488
| +245% | +$605K | 0.12% | 97 |
|
|
2019
Q3 | $164K | Sell |
76,020
-7,040
| -8% | -$15.2K | 0.03% | 348 |
|
|
2019
Q2 | $261K | Sell |
83,060
-123,413
| -60% | -$388K | 0.03% | 300 |
|
|
2019
Q1 | $768K | Buy |
+206,473
| New | +$768K | 0.11% | 87 |
|
|
2018
Q3 | – | Sell |
-45,069
| Closed | -$105K | – | 528 |
|
|
2018
Q2 | $105K | Buy |
+45,069
| New | +$105K | 0.01% | 317 |
|